Bristol-Myers Squibb has acquired privately held Amira Pharmaceuticals, for $325 million upfront, with potential additional milestone payments totaling $150 million. Amira is a small-molecule pharmaceutical company focused on the discovery and development of treatments for inflammatory and fibrotic diseases. BMS will gain Amira’s fibrosis program, including the lead asset AM152, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist entering Phase IIa proof-of-confidence studies...